TD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants with supplemental oxygenation),...
- Mechanism
- Curator reviewed
TD-0903 is a nebulized inhalation solution that inhibits janus kinase and selectively targets the lungs. This inhibition of JAK-STAT signalling aims to reduce complications associated with cytokine challenges in the airways. The anti-inflammatory mechanism associated with TD-0903 may reduce hyperinflammation in patients experiencing acute respiratory distress syndrome (ARDS).
- Formula / weight
- C30H37N7O2 · 527.673 g/mol (avg)
- Also known as
- (3-(DIMETHYLAMINO)AZETIDIN-1-YL)((6S)-2-(6-(2-ETHYL-4-HYDROXYPHENYL)-1H-INDAZOL-3-YL)-5-(PROPAN-2-YL)-4,5,6,7-TETRAHYDRO-1H-IMIDAZO(4,5-C)PYRIDIN-6-YL)METHANONE · (S)-(3-(DIMETHYLAMINO)AZETIDIN-1-YL)(2-(6-(2-ETHYL-4-HYDROXYPHENYL)-1H-INDAZOL-3-YL)-5-ISOPROPYL-4,5,6,7-TETRAHYDRO-3H-IMIDAZO(4,5-C)PYRIDIN-6-YL)METHANONE · METHANONE, (3-(DIMETHYLAMINO)-1-AZETIDINYL)((6S)-2-(6-(2-ETHYL-4-HYDROXYPHENYL)-1H-INDAZOL-3-YL)-4,5,6,7-TETRAHYDRO-5-(1-METHYLETHYL)-3H-IMIDAZO(4,5-C)PYRIDIN-6-YL)- · NEZULCITINIB
- Code names
- TD-0903 · THRX-136377
Resolves to
VQIIUJSNIKEMCK-MHZLTWQESA-NSMILESCCC1=C(C=CC(O)=C1)C1=CC=C2C(NN=C2C2=NC3=C(C[C@H](N(C3)C(C)C)C(=O)N3CC(C3)N(C)C)N2)=C1What you can answer from here — as of June 15, 2026
Which companies are running trials of TD-0903, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account